Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04808999
Title Neoadjuvant Study of PD-1 Inhibitor Pembrolizumab in PD-1 Naive Cutaneous Squamous Cell Carcinoma (cSCC)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Diwakar Davar
Indications

skin squamous cell carcinoma

Therapies

Pembrolizumab

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.